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Evidence-based strategies to guide human immunodeficiency virus (HIV) prevention for
people who use substances can be grouped into approaches that lower infectiousness
among substance users living with HIV and those that prevent HIV acquisition among
those who are uninfected. Dramatic successes in HIV prevention involving access to an-
tiretroviral therapy, opioid substitution therapies, and needle and syringe exchange pro-
grams have reduced both prevalence and incidence in the United States for people who use
injection drugs, andmodeling studies suggest that scale-up of these approaches will have a
parallel impact worldwide. Medical HIV-prevention strategies that reduce infectiousness
(“treatment as prevention” or early antiretroviral therapy initiation) and that block HIV
acquisition (pre-exposure prophylaxis and post-exposure prophylaxis) can constitute key
elements of novel combination HIV-prevention approaches to the goals of reducing
infectiousness and reducing acquisition of HIV among people who use substances. For
individuals who use substances but do not inject, drug dependence treatments as HIV
prevention have a meager evidence base, with most consistent findings being reduction of
sexual transmission behaviors that correspond with reductions in substance use, although
not with prevention of HIV transmission. This approach may have value, however, when
working with groups of substance users who face high rates of HIV prevalence and inci-
dence. Some evidence exists to support HIV prevention interventions that target reduction
of sexual risk behaviors in the setting of active stimulant use.
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LLC. Open access under CC BY-NC-ND license.1. Introduction behaviors engaged in while under the influence of substances.People who use substances can face multiple transmission
risks for human immunodeficiency virus (HIV) when the sub-
stances are used in the context of HIV prevalence. These
include behaviors related to injection drug use (e.g., needle
sharing or reusing needles) and to unprotected sexualool of Medicine at UCLA,
du (S. Shoptaw).
ministration, Taiwan. PublRemarkable successes in HIV prevention among people who
use injection drugs are evident where there is simultaneous
access to antiretroviral therapy (ART), opioid substitution
therapy, and needle and syringe exchange programs, including
impressive reductions in both incidence and prevalence of HIV
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can facilitate sexual transmission risks, especially amongMSM
who incorporate stimulants [3] and alcohol [4] with their sexual
behaviors. Among non-substance using MSM, biomedical HIV
prevention strategies reduce HIV transmission when imple-
mented with consistent condom use [5], although no data are
available to suggest whether this protective benefit can be
extended toward MSM who integrate substance use with their
sexual behaviors. This paper outlines evidence-based strategies
that can be used to guide a rational strategy for HIV prevention
among substance users; particularly for those who engage in
substance-related risks in the setting of high HIV prevalence,
and points toward future research and clinical efforts.
HIV prevention can be grouped into two approaches [6]:
strategies that prevent transmissions by reducing infectious-
ness in those living with HIV; and strategies that increase
protection against acquisition of HIV infection among those
who are at high risk (Table 1) [5,7–14].2. Lowering infectiousness in substance
users living with HIV
Suppressing viremia using ART in people living with HIV in-
creases the health of HIV-infected individuals and reduces
odds for transmission [15]. In a landmark trial, findings
showed that compared to standard ART, those randomized to
receive comprehensive ART early in HIV infection had less
HIV-related morbidity. Moreover, the likelihood for HIV
transmission to the uninfected partner from the partner
receiving early ART was reduced by 96% [7]. The provision of
ART early in HIV infection, which protects against HIV trans-
mission in stable serodiscordant partners, has been named
“treatment as prevention” (TasP).
No one knows whether TasP confers parallel health and
prevention benefits for substance users living with HIV and
who are in serodiscordant partnerships. Studies now are
being planned to test whether implementing ART early in HIV
infection in the context of opioid substitution therapy,
consistent condom use, and access to needle and syringe
exchange will enhance health for people who use injection
drugs and prevent transmission to serodiscordant partners.
Although there are no data to address whether TasP will work
in the setting of active injection drug use, it is known that ART
taken consistently produces viral suppression in a parallelTable 1 e Evidence-based HIV-prevention strategies for
people who use substances.




Antiretroviral therapy as HIV
prevention [7]
Pre-exposure prophylaxis [5]
Opioid substitution therapy [8] Post-exposure prophylaxis [9]








HIV ¼ human immunodeficiency virus.fashion for people living with HIV who inject drugs and those
who do not use drugs [16]. Among HIV-positive MSM, the
immune-enhancing effects of adherence to ART are signifi-
cantly greater than themodest cumulative negative effects on
immune function due to reported use of either cocaine or
methamphetamine [17]. Despite this, people who use drugs
face consistent barriers to acquiring access to ART. Findings
from a Canadian cohort show that people who use drugs (both
injection and non-injection) have between a 53% and 38%
lower likelihood (respectively) of ever having access to ART
compared to people living with HIV who do not use drugs [18].
Among people who inject drugs, opioid substitution ther-
apy is an efficacious HIV-prevention strategy. Compared to
people not in opioid substitution therapy, people who inject
drugs and who are in opioid substitution therapy are more
likely to initiate ART and, once started, are more likely to
adhere to ART [19,20]. Even among homeless individuals,
methadone maintenance doubles the odds for viral suppres-
sion compared to those not on methadone [21]. Opioid sub-
stitution therapies (methadone and buprenorphine) act to
prevent HIV transmission along multiple mechanisms,
including reduction of illicit opioid use (and number of in-
jections), sharing of injection equipment (and potential
transmission events), and multiple sex partners and ex-
changes of sex for drugs or money (and number of drug-
associated sexual transmission episodes) [8].
Whether or not people who inject drugs are engaged in
opioid substitution therapy, needle and syringe exchange
programs provide protection against HIV transmission by
facilitating access to sterile injection equipment, to supplies
that promote health and prevent disease, and to linkages to
primary and HIV medical care [10]. Indeed, simultaneous
scale-up of access to ART, opioid substitution therapy, and
needle and syringe exchange programs is estimated to reduce
HIV incidence among people who inject drugs by>60% [22,23].
Additional HIV-prevention approaches are recommended for
people who inject drugs by the World Health Organization,
UNAIDS, and the United Nations Office on Drugs and Crime,
and include HIV counseling and testing, prevention and
treatment of sexually transmitted infections, condom pro-
grams for people who use substances and their sexual part-
ners, targeted information, education and communication
programs, prevention vaccination and treatment for viral
hepatitis, and voluntary medical male circumcision [24].
Interestingly, one randomized controlled trial showed efficacy
for sustained reduction of HIV sexual transmission behaviors
among non-treatment-seeking stimulant users [13].3. Preventing acquisition of HIV for
substance users
Acquisition of HIV can be prevented using pre-exposure pro-
phylaxis (PrEP), which entails providing ART prophylactically
to HIV-negative individuals who experience regular exposures
to HIV. Evidence for the approach is a randomized placebo
controlled trial involving 2499 MSM or transgender women
who were assigned to receive a daily combination tablet of
tenofovir and emtricitabine or placebo. Those assigned to
active medication showed 43% reduction in HIV infection
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participants in the active condition who were highly adherent
to their medication [5]. Initial evidence suggests that people
who inject drugs may experience protection using PrEP, with
one placebo-controlled randomized trial of daily oral tenofovir
in the context of methadone maintenance and needle and
syringe exchange programs showing efficacy over placebo in
preventing HIV acquisition, particularly at long-term follow-
up evaluations [25]. Although preliminary, this evidence sug-
gests a PrEP strategy is appropriate for high-risk substance
users, although the specifics defining the sample of substance
users (injection, non-injecting, MSM, heterosexual, opioids,
stimulants) and the contextual components in which the
prophylactic medication is delivered (addiction treatment,
harm reduction, sexually transmitted infection clinics) have
yet to be articulated.
Although no randomized clinical trials of HIV medication
or behavioral prevention interventions have demonstrated
significant reductions in HIV incidence among HIV-negative
individuals (independent of substance use), post-exposure
prophylaxis (PEP; starting ART among HIV-negative in-
dividuals within 72 hours after potential exposure to HIV) is
recommended in occupational and nonoccupational contexts
[26]. PEP strategies have been evaluated favorably when used
among MSM [9]. When PEP is integrated with contingency
management among MSM who have methamphetamine
dependence and engage in concomitant high-risk sexual
behaviors, positive response to contingency management
increased completion rates for the PEP regimen [14]. Showing
a preliminary signal for stimulant-drug-dependence treat-
ment as HIV prevention, one randomized controlled trial
showed that methamphetamine-dependent MSM assigned to
receive mirtazapine (30 mg/day) significantly reduced meth-
amphetamine use and high-risk sexual behaviors [11]. More
careful evaluations are needed to determine whether drug-
dependence treatments can function in part or in whole as
HIV-prevention strategies in groups of substance users at high
risk for HIV acquisition due to drug-related sexual trans-
mission behaviors.4. Summary and conclusions
Taken together, a database exists that can guide composition
of novel combination HIV-prevention approaches for people
who use drugs and encounter HIV transmission risks. Strong
evidence suggests that people who use substances can benefit
from TasP; weaker evidence indicates PrEP may provide pro-
phylaxis against HIV transmission when delivered in specific
contexts for people who inject drugs. Strong signals demon-
strate that opioid substitution therapy enhances immune
functioning among people who use drugs receiving ART and is
efficacious on its own as an HIV-prevention strategy among
HIV-negative people who inject drugs. Future directions in
research will articulate ways in which ART and efficacious
medications for substance dependence can constitute novel
combination HIV-prevention strategies that will ultimately
reduce infectiousness among HIV-positive substance users
and prevent HIV acquisition among those who are HIV
negative.r e f e r e n c e s
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